Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
AstraZeneca
Merck
Express Scripts

Last Updated: June 29, 2022

Investigational Drug Information for Puerarin


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Puerarin?

Puerarin is an investigational drug.

There have been 7 clinical trials for Puerarin. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Alcoholism. The leading clinical trial sponsors are Chengdu PLA General Hospital, The University of Hong Kong, and Jiangxi University of Traditional Chinese Medicine.

Recent Clinical Trials for Puerarin
TitleSponsorPhase
Pueraria Lobata and Pueraria Thomsonii for Mild DyslipidemiaJiangxi University of Traditional Chinese MedicineN/A
Effect of Puerarin on Heart Health in MenHealth and Medical Research FundPhase 2
Effect of Puerarin on Heart Health in MenHealth and Medical Research Fund, Hong KongPhase 2

See all Puerarin clinical trials

Clinical Trial Summary for Puerarin

Top disease conditions for Puerarin
Top clinical trial sponsors for Puerarin

See all Puerarin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
AstraZeneca
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.